Atlases
Three in build. A designed pipeline behind them.
Every locus resolved to the single base, across the whole genome. Lanes are cell-type platforms — everything inside a validated lane can start immediately.
Scroll the figure sideways to see every lane
Atlas pipeline, as a table
| Cell platform | Indication | Status | Published loci |
|---|---|---|---|
| T-cell | Pediatric Immunology | In Build | — |
| T-cell | Leukemia (Pediatric) | In Build | — |
| T-cell | Leukemia (Adult) | In Build | — |
| T-cell | Inflammatory bowel disease | In Design | 320+ |
| T-cell | Rheumatoid arthritis | In Design | 100+ |
| T-cell | Lupus (SLE) | In Design | 100+ |
| T-cell | Asthma | In Design | 100+ |
| T-cell | Psoriasis | In Design | 80+ |
| T-cell | Atopic dermatitis | In Design | 75+ |
| Fibroblast | Gastrointestinal disease | In Design | — |
| Fibroblast | Undisclosed | In Design | — |
| Fibroblast | Undisclosed | In Design | — |
| iPSC | Open lane — partner-nominated | Invitation | — |
Throughput
10,000s
Variants edited and read out in parallel, in a single run.
Design → AI insights
1 quarter
The pipeline is built to go from variant library to queryable Atlas within a quarter.
Resolution
1 bp
Single-nucleotide causal effect, not regional association.
Cell platforms
2
T-cell validated and running; fibroblast in stand-up. iPSC is open and not yet built.
Counts reflect published literature screened during pipeline design. In Build indications sit in a validated, running lane. Indications marked In Design are scoped but are not committed programs.
Collaborate
Which variants would you test if you could?
A GWAS never functionally resolved. A platform that needs a causal layer. A model that needs ground truth.